Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Jefferies analyst Roger Song initiates coverage on aTyr Pharma (NASDAQ:ATYR) with a Buy rating and announces Price Target of...
HC Wainwright & Co. analyst Joseph Pantginis reiterates aTyr Pharma (NASDAQ:ATYR) with a Buy and maintains $35 price tar...
RBC Capital analyst Gregory Renza reiterates aTyr Pharma (NASDAQ:ATYR) with a Outperform and maintains $16 price target.
aTyr Pharma (NASDAQ:ATYR) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.25) b...
HC Wainwright & Co. analyst Joseph Pantginis reiterates aTyr Pharma (NASDAQ:ATYR) with a Buy and maintains $35 price tar...
aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or "the Company"), a clinical stage biotechnology company engaged in th...
HC Wainwright & Co. analyst Joseph Pantginis reiterates aTyr Pharma (NASDAQ:ATYR) with a Buy and maintains $35 price tar...
